Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635516 | 0.95 | HRH3 (0.38) | HRH3ESR1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL12635519 | 0.95 | HRH3 (0.38) | HRH3ESR1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL26263997 | 0.89 | RXRA (0.39) | HRH3ESR1CYP17A1CYP21A2CYP11B1 | |
| SCHEMBL18308717 | 0.89 | MEN1 (0.41) | HRH3ESR1CYP17A1CYP11B1TAAR1 | |
| SCHEMBL18308814 | 0.87 | RXRA (0.37) | HRH3ESR1RXRARXRB | |
| SCHEMBL12214232 | 0.86 | HRH3 (0.47) | HRH3ESR1CYP17A1CYP11B1TAAR1 | |
| SCHEMBL18308709 | 0.86 | HRH3 (0.47) | HRH3ESR1CYP17A1CYP11B1TAAR1 | |
| SCHEMBL20382347 | 0.85 | HRH3 (0.35) | HRH3ESR1TAAR1 | |
| SCHEMBL20382346 | 0.83 | RXRA (0.41) | HRH3ESR1RXRARXRB | |
| SCHEMBL18308720 | 0.82 | MEN1 (0.48) | HRH3ESR1CYP17A1CYP11B1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760935-B2 | Polymerizable compounds | MERCK PATENT GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11739266-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20180201837-A1 | Method of Reducing ODF Mura in Polymer Stabilised Liquid Crystal Displays | MERCK PATENT GMBH (DE) | 2018-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760935-B2 | Polymerizable compounds | PARG, PHOSPHO1, PARN | HRH3 3365/4885ESR1 2230/4885CYP17A1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.